Cephalon Inc. v. Hospira Inc.
1:14-cv-01242
π‘ 5G SEP β’ ETSI DeclaredOverview
Parties
Defendant
Hospira Inc. Operating Company
Represented By
2 Attorneys ListedYoung, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Young, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Plaintiff
Cephalon Inc. Operating Company
Represented By
2 Attorneys ListedShaw Keller LLP
1105 North Market Street, 12th Floor, Wilmington, DE 19801
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 9 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 8,791,270 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2014014849 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2015037467 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2018029653 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2020023772 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 64,435,405 P | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 8,436,190 B2 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 8,461,350 B2 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 8,895,756 B2 | US Continuation / Sibling | View Official Patent → |
Fresenius Kabi USA, LLC v. Cephalon, Inc.
AGILA SPECIALTIES INC. et al. v. Cephalon, Inc.
AGILA SPECIALTIES INC. v. Cephalon, Inc.
Standard Essential Patent (SEP) & FRAND Intelligence
5G SEP β’ ETSI Declared High-Probability SEP ActionEssential standard specifications, SSO declaration status, and FRAND antitrust defense evaluation
Injunction Restrictions & FRAND Defense Leverage (CJEU Huawei v. ZTE Framework)
Permanent Injunction RestrictedAsserted by recognized SEP declarant. Under the CJEU Huawei v. ZTE test, injunctions are barred if the defendant qualifies as a willing licensee.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US8791270
Bendamustine pharmaceutical compositions
|
Filed: 2013-08-19
Issued: 2014-07-29
|
Active (6.7 yrs remaining)
Expires: 2033-08-19
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.
Standard Statutory Term β No obviousness-type double patenting truncation noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
3
Dispositive
1
Granted
0
Denied
0
Pending / Review
0
Motions by Category
Key Dispositive Motions & Rulings